Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...

Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...

Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in...